EPISODE · Aug 3, 2026 · 17 MIN
Recent Advances, Future Directions, and Ideas on Integrating CELMoDs Into The Care Of Patients With Myeloma
from Decera Clinical Education Oncology Podcast · host Sagar Lonial MD, Mohamad Mohty MD PhD
Listen in to learn from Sagar Lonial, MD, and Mohamad Mohty MD, PhD, about the advantages and future implications of the next-generation protein degradation modulator based therapy and find out how to integrate their use into your practice. Presenters:Sagar Lonial, MD, FACP, FASCO Chair and Professor Department of Hematology and Medical Oncology Anne and Bernard Gray Family Chair in Cancer Chief Medical Officer Winship Cancer Institute Emory University School of Medicine Atlanta, Georgia Mohamad Mohty, MD, PhD Sorbonne University Paris, France Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Visit the program page for more content associated with this discussion. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Embed this episode
What this episode covers
Listen to this podcast to hear Sagar Lonial, MD, FACP, FASCO, and Mohamad Mohty, MD, PhD, discuss recent advances, future directions, and the integration of novel protein degradation modulator-based therapy into myeloma care, including what clinicians may expect when incorporating these therapies into practice.
NOW PLAYING
Recent Advances, Future Directions, and Ideas on Integrating CELMoDs Into The Care Of Patients With Myeloma
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.